319 related articles for article (PubMed ID: 29753548)
1. Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis.
Sidana A; Watson MJ; George AK; Rastinehad AR; Vourganti S; Rais-Bahrami S; Muthigi A; Maruf M; Gordetsky JB; Nix JW; Merino MJ; Turkbey B; Choyke PL; Wood BJ; Pinto PA
Urol Oncol; 2018 Jul; 36(7):341.e1-341.e7. PubMed ID: 29753548
[TBL] [Abstract][Full Text] [Related]
2. Changes in prostate cancer detection rate of MRI-TRUS fusion vs systematic biopsy over time: evidence of a learning curve.
Calio B; Sidana A; Sugano D; Gaur S; Jain A; Maruf M; Xu S; Yan P; Kruecker J; Merino M; Choyke P; Turkbey B; Wood B; Pinto P
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):436-441. PubMed ID: 28762373
[TBL] [Abstract][Full Text] [Related]
3. A Comparison of Cancer Detection Rates Between Template Systematic Biopsies Obtained Using Magnetic Resonance Imaging-Ultrasound Fusion Machine and Freehand Transrectal Ultrasound-Guided Systematic Biopsies.
Hoge C; Maynor S; Guan T; Naffouje R; Rao M; Verma S; Sidana A
J Endourol; 2020 Oct; 34(10):1095-1098. PubMed ID: 32631097
[No Abstract] [Full Text] [Related]
4. Multiparametric MRI/ultrasound fusion-guided biopsy decreases detection of indolent cancer in African-American men.
Kongnyuy M; Siddiqui MM; George AK; Muthigi A; Sidana A; Maruf M; Turkbey B; Choyke PL; Wood BJ; Pinto PA
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):348-351. PubMed ID: 28440325
[TBL] [Abstract][Full Text] [Related]
5. Midline lesions of the prostate: role of MRI/TRUS fusion biopsy and implications in Gleason risk stratification.
Muthigi A; Sidana A; George AK; Kongnyuy M; Shakir N; Kadakia M; Maruf M; Frye TP; Mertan F; Su D; Merino MJ; Choyke PL; Turkbey B; Wood BJ; Pinto PA
Int Urol Nephrol; 2016 Sep; 48(9):1445-52. PubMed ID: 27305918
[TBL] [Abstract][Full Text] [Related]
6. Multiparametric MRI-ultrasound fusion prostate biopsy in patients without prior diagnosis of prostate cancer: beyond centers of excellence.
Verma S; Zegar J; Hoge C; McGready J; Sidana A
Aging Male; 2020 Dec; 23(5):1570-1575. PubMed ID: 33446002
[TBL] [Abstract][Full Text] [Related]
7. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
8. The prostate cancer prevention trial risk calculator 2.0 performs equally for standard biopsy and MRI/US fusion-guided biopsy.
Maruf M; Fascelli M; George AK; Siddiqui MM; Kongnyuy M; DiBianco JM; Muthigi A; Valayil S; Sidana A; Frye TP; Kilchevsky A; Choyke PL; Turkbey B; Wood BJ; Pinto PA
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):179-185. PubMed ID: 28220802
[TBL] [Abstract][Full Text] [Related]
9. Accuracy of elastic fusion biopsy: Comparing prostate cancer detection between targeted and systematic biopsy.
Oderda M; Albisinni S; Benamran D; Calleris G; Ciccariello M; Dematteis A; Diamand R; Descotes JL; Fiard G; Forte V; Giacobbe A; Marquis A; Marra G; Messas A; Muto G; Peltier A; Rius L; Simone G; Roumeguere T; Faletti R; Gontero P
Prostate; 2023 Feb; 83(2):162-168. PubMed ID: 36259316
[TBL] [Abstract][Full Text] [Related]
10. Predictive clinical features for negative histopathology of MRI/Ultrasound-fusion-guided prostate biopsy in patients with high likelihood of cancer at prostate MRI: Analysis from a urologic outpatient clinic1.
Apfelbeck M; Pfitzinger P; Bischoff R; Rath L; Buchner A; Mumm JN; Schlenker B; Stief CG; Chaloupka M; Clevert DA
Clin Hemorheol Microcirc; 2020; 76(4):503-511. PubMed ID: 33337358
[TBL] [Abstract][Full Text] [Related]
11. Postoperative change in Gleason score of prostate cancer in fusion targeted biopsy: a matched pair analysis.
Apfelbeck M; Tritschler S; Clevert DA; Buchner A; Chaloupka M; Kretschmer A; Herlemann A; Stief C; Schlenker B
Scand J Urol; 2021 Feb; 55(1):27-32. PubMed ID: 33380254
[TBL] [Abstract][Full Text] [Related]
12. Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging.
Chaloupka M; Bischoff R; Pfitzinger P; Lellig E; Ledderose S; Buchner A; Schlenker B; Stief C; Clevert DA; Apfelbeck M
Clin Hemorheol Microcirc; 2019; 73(1):105-111. PubMed ID: 31561351
[TBL] [Abstract][Full Text] [Related]
13. Optimizing Combined Magnetic Resonance Imaging (MRI)-Targeted and Systematic Biopsy Strategies: Sparing the Multiparametric MRI-Negative Transitional Zone in Presence of Exclusively Peripheral Multiparametric MRI-Suspect Lesions.
Kachanov M; Leyh-Bannurah SR; Roberts MJ; Sauer M; Beyersdorff D; Boiko S; Maurer T; Steuber T; Graefen M; Budäus L
J Urol; 2022 Feb; 207(2):333-340. PubMed ID: 34555925
[TBL] [Abstract][Full Text] [Related]
14. The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men.
Kongnyuy M; Sidana A; George AK; Muthigi A; Iyer A; Fascelli M; Kadakia M; Frye TP; Ho R; Mertan F; Minhaj Siddiqui M; Su D; Merino MJ; Turkbey B; Choyke PL; Wood BJ; Pinto PA
Urol Oncol; 2016 Jun; 34(6):254.e15-21. PubMed ID: 26905304
[TBL] [Abstract][Full Text] [Related]
15. The combination of targeted and systematic prostate biopsies is the best protocol for the detection of clinically significant prostate cancer.
Fourcade A; Payrard C; Tissot V; Perrouin-Verbe MA; Demany N; Serey-Effeil S; Callerot P; Coquet JB; Doucet L; Deruelle C; Joulin V; Nonent M; Fournier G; Valeri A
Scand J Urol; 2018 Jun; 52(3):174-179. PubMed ID: 29463177
[TBL] [Abstract][Full Text] [Related]
16. Patient Experience of Systematic Versus Fusion Prostate Biopsies.
Eineluoto JT; Järvinen P; Kilpeläinen T; Lahdensuo K; Kalalahti I; Sandeman K; Mirtti T; Rannikko A
Eur Urol Oncol; 2018 Aug; 1(3):202-207. PubMed ID: 31102622
[TBL] [Abstract][Full Text] [Related]
17. mpMRI-targeted biopsy of the prostate in men ≥ 75 years. 7-year report from a high-volume referral center.
Chaloupka M; Pyrgidis N; Ebner B; Pfitzinger PL; Volz Y; Berg E; Enzinger B; Atzler M; Ivanova T; Pfitzinger PL; Stief CG; Apfelbeck M; Clevert DA
Clin Hemorheol Microcirc; 2024; 86(1-2):63-70. PubMed ID: 37718788
[TBL] [Abstract][Full Text] [Related]
18. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?
Osses DF; Drost FH; Verbeek JFM; Luiting HB; van Leenders GJLH; Bangma CH; Krestin GP; Roobol MJ; Schoots IG
BJU Int; 2020 Jul; 126(1):124-132. PubMed ID: 32232921
[TBL] [Abstract][Full Text] [Related]
20. The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy.
Patel N; Cricco-Lizza E; Kasabwala K; Xu C; Robinson BD; Khani F; Wang Y; Margolis D; Hu JC
Eur Urol Oncol; 2018 Sep; 1(4):263-267. PubMed ID: 31100246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
